Glycomimetics Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the areas of cancer and rare blood disorders
The company specializes in creating glycomimetic drugs, which are designed to replicate the functionality of carbohydrates that play crucial roles in biological processes, including cell adhesion and interaction. By harnessing this technology, Glycomimetics aims to target and disrupt disease mechanisms, thereby improving treatment options and outcomes for patients. Their pipeline includes a range of drug candidates that are undergoing clinical trials, highlighting their commitment to advancing medical science and enhancing patient care.
GlycoMimetics, Inc. (NASDAQGLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance its oncology pipeline.
Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses.
